Acorda Therapeutics Licenses Preclinical Drug Nepicastat to China’s Asieris
US-based Acorda Therapeutics Inc. (Nasdaq: ACOR) announced a licensing agreement with China’s Asieris Pharmaceuticals for...
SAMR Issues New Rules for Online Drug Sales in China
China’s State Administration for Market Regulation (SAMR) has released the “Measures for the Supervision and...
NMPA Designates Shijiazhuang Airport as Drug Import Port for Narcotics, Psychotropics
China’s National Medical Products Administration (NMPA) has designated Shijiazhuang Airport in Hebei Province as an...
Henlius Biotech Plans US Bridging Study for Serplulimab in ES-SCLC
Shanghai Henlius Biotech (HKG: 2696) is advancing its checkpoint inhibitor serplulimab toward the U.S. market,...
RedCloud Bio Doses First Patient in H002 EGFR TKI Phase I/IIa Trial for NSCLC
Shanghai-based RedCloud Bio announced that the first patient has been dosed in a Phase I/IIa...
Lepu Biopharma’s MRG002 Earns FDA Orphan Drug Status for Gastric Cancer
China’s Lepu Biopharma Co., Ltd (HKG: 2157) announced that the U.S. FDA has granted orphan...
CDE Releases 62nd Batch of Chemical Generic References, Updates 39 Specifications
The Center for Drug Evaluation (CDE) has released the 62nd batch of chemical generic reference...
Jacobio Pharmaceuticals Doses First Patient in JAB-21822 Phase IIa Trial for KRAS G12C NSCLC
China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) announced the first patient dosed in a...
Novartis Partners with Beijing’s Changping District to Expand Drug Development
Swiss pharma giant Novartis (NYSE: NVS) has partnered with Beijing’s Changping district government to expand...
GenScript Biotech’s H1 2022 Revenue Rises 32.7% on Carvykti CAR-T Sales
Nanjing-based GenScript Biotech, a biopharma and contract research firm, reported a 32.7% year-on-year (YOY) revenue...
Mayo Clinic Launches Mayflower BioVentures to Accelerate Cell and Gene Therapies
The Mayo Clinic, a leading US hospital group, has launched Mayflower BioVentures, a cell and...
Biointron Raises USD 72M in Series B to Expand CRO Services and Antibody Platform
Shanghai-based Biointron, a recombinant protein/antibody reagent contract research organization (CRO), has raised nearly RMB 500...
Simcere Pharma’s H1 2022 Revenue Rises 27% on New Drug Sales, R&D Push
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) reported RMB 2.7 billion (USD 391 million) in...
Alphamab Oncology Reports H1 2022 Revenue Growth Driven by Envafolimab Commercialization
China-based Alphamab Oncology (HKG: 9966) reported RMB 53.57 million (USD 7.7 million) in H1 2022...
Akeso Bio’s AK112 Wins Breakthrough Designation for First-Line NSCLC
China’s Akeso Bio has secured a breakthrough therapy designation (BTD) from the Center for Drug...
RemeGen’s H1 2022 Revenue Soars 1,094% on Aidixi, Taiai Sales
China-based biotech RemeGen (HKG: 9995) reported RMB 349 million (USD 50.5 million) in revenue for...
Beijing Adjusts UEBMI Account Management, Boosting Outpatient Coverage
The Beijing Municipal Medical Insurance Bureau has adjusted the management of Urban Employee Basic Medical...
Junshi Biosciences’ H1 2022 Financials Show Tuoyi Sales Growth Despite Revenue Drop
Shanghai-based Junshi Biosciences (HKG: 1877) reported a 55.26% year-on-year (YOY) revenue decline to RMB 946.05...
Connect Biopharma Completes Phase I Trial of CBP-174 for Itch in Skin Diseases
Sino-US biotech Connect Biopharma Holdings Ltd (NASDAQ: CNTB), headquartered in San Diego, California, and Taicang,...
RoosterBio Taps MBL Beijing Biotech as Exclusive Distributor in China
US-based RoosterBio Inc. has appointed MBL Beijing Biotech, a subsidiary of JSR Life Sciences Company,...